In a randomised, phase II study in patients with recurrent non-small cell lung cancer, onartuzumab plus erlotinib was associated with improved progression-free survival and overall survival in the MET-positive population. These results combined with the worse outcomes observed in MET-negative patients treated with onartuzumab highlight the importance of diagnostic testing in drug development, according to conclusion of the article published by Dr David Spigel of the Sarah Cannon Research Institute, Nashville, USA and colleagues. Read more here.
Study mentioned: Spigel DR, et al. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2013 Nov 10;31(32):4105-14. PMID: 24101053
No comments:
Post a Comment